GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, W12 0NN, UK.
Org Biomol Chem. 2011 May 7;9(9):3313-9. doi: 10.1039/c0ob00631a. Epub 2011 Mar 25.
Microfluidic technology has been used to perform [(11)C]carbonylation reactions using solutions containing [(11)C]CO in the form of the complex, copper(i)tris(3,5-dimethylpyrazolyl)borate-[(11)C]carbonyl (Cu(Tp*)[(11)C]CO). The synthesis of the model compound [(11)C]N-benzylbenzamide and the known tracer molecule [(11)C]trans-N-[5-(2-flurophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofurane-1(3H),1'-cyclohexane]-4'-carboxamide ([(11)C]MK-0233), a ligand for the neuropeptide Y Y5 receptor, have been performed using this technique. Following semi-preparative HPLC purification and reformulation, 1262 ± 113 MBq of [(11)C]MK-0233 was produced at the end of the synthesis with a specific activity of 100 ± 30 GBq μmol(-1) and a >99% radiochemical purity. This corresponds to a decay corrected radiochemical yield of 7.2 ± 0.7%. Using a 3 mL vial as the reaction vessel, and following semi-preparative HPLC purification and reformulation, 1255 ± 392 MBq of [(11)C]MK-0233 was produced at the end of the synthesis with a specific activity of 100 ± 15 GBq μmol(-1) and a >99% radiochemical purity. This corresponds to a decay corrected radiochemical yield of 7.1 ± 2.2%.
微流控技术已被用于使用含有 [(11)C]CO 的溶液进行 [(11)C] 羰基化反应,其中 [(11)C]CO 以铜 (I) 三 (3,5-二甲基吡唑基) 硼酸-[(11)C] 羰基 (Cu(Tp*)[(11)C]CO) 的形式存在。模型化合物 [(11)C]N-苄基苯甲酰胺和已知示踪剂分子 [(11)C]trans-N-[5-(2-氟苯基)-2-嘧啶基]-3-氧代螺[5-氮杂异苯并呋喃-1(3H),1'-环己烷]-4'-羧酸酯 ([(11)C]MK-0233) 的合成已使用该技术完成,该化合物是神经肽 Y Y5 受体的配体。在半制备型 HPLC 纯化和重新配方后,[(11)C]MK-0233 的合成结束时产生了 1262±113MBq,比活度为 100±30GBqμmol(-1),放射化学纯度>99%。这相当于衰减校正后的放射化学产率为 7.2±0.7%。使用 3mL 小瓶作为反应容器,在半制备型 HPLC 纯化和重新配方后,[(11)C]MK-0233 的合成结束时产生了 1255±392MBq,比活度为 100±15GBqμmol(-1),放射化学纯度>99%。这相当于衰减校正后的放射化学产率为 7.1±2.2%。